Clovis Oncology
Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer
October 11, 2019Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma
NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …
Clovis Oncology discontinue phase 2 bladder cancer trial
April 15, 2019Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer
Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …
Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show
April 3, 2019Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma
At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …
FDA staff raises doubts on efficacy, safety of Clovis’ trial drug for lung cancer, shares plunge
April 11, 2016AstraZeneca, Clovis Oncology, US FDA, drug trial, lung cancer, regulation, rociletinib
Shares in Clovis Oncology Inc (Nasdaq: CLVS) plunged to close down nearly 18% after the US regulators expressed doubts if …
Latest content
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
